- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Insurance Coverage and Recovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- Careers
- News & Insights
- About
- Languages
Nikki Reeves
Insight 27 results
Client Alert
September 24, 2020
FDA Proposes New Rule Modifying its “Intended Use” Regulations
Client Alert
April 17, 2020
Europe Update – Life Sciences Products and COVID-19: From Clinical Trials to Regulatory Flexibility
Client Alert
March 23, 2020
U.S. and EU Regulators and Institutions Issue Guidance on Clinical Trial Conduct during COVID-19 Pandemic
Client Alert
March 19, 2020
FDA Regulatory Issues for Automakers Manufacturing Medical Devices
Article · Source: Chambers and Partners
March 2, 2020
Chambers Global Practice Guide: Pharmaceutical Advertising
Client Alert
February 28, 2020
2019 Year in Review: FDA Office of Prescription Drug Promotion
Client Alert
February 7, 2020
FDA Releases Draft Guidance on Promotion of Biological Reference and Biosimilar Products
Client Alert
September 27, 2019
FDA Issued Draft Objective Performance Criteria For Five Device Types
Article · Source: Health Care Compliance Professional’s Manual
Client Alert
January 9, 2019
AdvaMed Updates Code of Ethics on Interactions with U.S. Health Care Professionals
Client Alert
December 3, 2018
FDA Announces “Modernization” Reforms to Medical Device Review Process